Atrinsic (NASDAQ:PTIX) Shares Up 6.2% – Should You Buy?

Atrinsic Inc. (NASDAQ:PTIX)’s share price traded up 6.2% during mid-day trading on Thursday . The stock traded as high as $0.6583 and last traded at $0.6583. 34,356 shares were traded during mid-day trading, a decline of 94% from the average session volume of 549,151 shares. The stock had previously closed at $0.62.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Atrinsic from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Weiss Ratings restated a “sell (e)” rating on shares of Atrinsic in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Atrinsic Price Performance

The business has a 50 day simple moving average of $1.67 and a 200 day simple moving average of $2.77. The company has a market cap of $1.27 million, a price-to-earnings ratio of -0.08 and a beta of 0.51.

Atrinsic (NASDAQ:PTIX) last released its quarterly earnings results on Wednesday, November 26th. The company reported ($0.47) earnings per share (EPS) for the quarter.

Atrinsic Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.